- Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences
- Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results
- Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy
- Kodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform
Key statistics
On Wednesday, Kodiak Sciences Inc (KOD:NMQ) closed at 2.20, 60.58% above the 52 week low of 1.37 set on Oct 27, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.24 |
---|---|
High | 2.26 |
Low | 2.19 |
Bid | 2.15 |
Offer | 2.33 |
Previous close | 2.24 |
Average volume | 369.76k |
---|---|
Shares outstanding | 52.53m |
Free float | 49.56m |
P/E (TTM) | -- |
Market cap | 117.68m USD |
EPS (TTM) | -4.44 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 18:00 BST.
More ▼